Assenagon Asset Management
OVID icon

Assenagon Asset Management’s Ovid Therapeutics OVID Stock Holding History

Assenagon Asset Management’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$47.2K Sell
17,544
-210,198
-92% -$542K ﹤0.01% 1156
2026
Q1 		$506K Sell
227,742
-390,277
-63% -$698K ﹤0.01% 1004
2025
Q4 		$1.01M Sell
618,019
-306,557
-33% -$472K ﹤0.01% 943
2025
Q3 		$1.2M Buy
924,576
+488,956
+112% +$424K ﹤0.01% 898
2025
Q2 		$144K Sell
435,620
-125,210
-22% -$37.7K ﹤0.01% 1126
2025
Q1 		$175K Buy
560,830
+490,716
+700% +$302K ﹤0.01% 1117
2024
Q4 		$65.5K Sell
70,114
-16,175
-19% -$18.1K ﹤0.01% 1298
2024
Q3 		$102K Buy
+86,289
New +$90.2K ﹤0.01% 1347
2024
Q2 		– Sell
-114,265
Closed -$349K – 1474
2024
Q1 		$349K Buy
114,265
+35,786
+46% +$120K ﹤0.01% 1265
2023
Q4 		$253K Buy
+78,479
New +$268K ﹤0.01% 1346
2022
Q3 		– Sell
-26,362
Closed -$57K – 1497
2022
Q2 		$57K Buy
+26,362
New +$63.7K ﹤0.01% 1423
2021
Q4 		– Sell
-334,589
Closed -$1.12M – 1524
2021
Q3 		$1.12M Buy
+334,589
New +$1.22M ﹤0.01% 874
2020
Q3 		– Sell
-510,302
Closed -$3.76M – 1299
2020
Q2 		$3.76M Buy
510,302
+390,242
+325% +$1.83M 0.02% 404
2020
Q1 		$358K Buy
120,060
+54,154
+82% +$182K ﹤0.01% 692
2019
Q4 		$274K Buy
+65,906
New +$208K ﹤0.01% 708

Other funds holding OVID

BMC
Benin Management Corp Wilton, Connecticut $494M AUM 25.95% 1-Year Est. Return
AWA
Aaron Wealth Advisors Chicago, Illinois $1.97B AUM 36.91% 1-Year Est. Return
TFM
TFC Financial Management Boston, Massachusetts $902M AUM 21.74% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $516M AUM 28.38% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Assenagon Asset Management's OVID Position: Q2 2026 in Review

Assenagon Asset Management reduced its Ovid Therapeutics (OVID) stake by 92% in Q2 2026, selling an estimated $542K and leaving 17,544 shares worth $47.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1156.

Assenagon Asset Management first reported a position in OVID in Q4 2019 and has held it in 15 quarters since. The position peaked at $3.76M in Q2 2020. 6 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

  • Assenagon Asset Management held 17,544 shares of Ovid Therapeutics worth $47.2K as of Q2 2026.
  • Assenagon Asset Management sold 210,198 Ovid Therapeutics shares in Q2 2026, an estimated $542K.
  • Ovid Therapeutics made up ﹤0.01% of Assenagon Asset Management's portfolio in Q2 2026, its #1156 holding.
  • Assenagon Asset Management first reported a position in Ovid Therapeutics in Q4 2019 and has held it in 15 quarters since.
  • Assenagon Asset Management's Ovid Therapeutics position peaked at $3.76M in Q2 2020.
  • 6 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on Assenagon Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.